Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models

Mishra, Rasmi R.; Kneitz, Susanne; Schartl, Manfred

doi:10.1016/j.cbpc.2014.01.002

Cited by 23 publications

(17 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There is fair evidence from others to support our results. Mishra et al reported that miRNAs of the miR-17-92 cluster (miR20a2, miR-92a1, miR-17 and miR-18a) were upregulated and RUNX1 gene was downregulated in melanoma [41]. However, it is not clear whether RUNX1 is involved in regulation of GEC function and increasing of BTB permeability mediated by miR-18a.…”

Section: Discussionmentioning

confidence: 97%

MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5

Miao

Zhao

et al. 2015

Cellular Signalling

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 97%

MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5

Miao

Zhao

et al. 2015

Cellular Signalling

View full text Add to dashboard Cite

“…These five miRNAs have not been extensively studied in terms of resistance to BRAF inhibitors; however, some play oncogenic or tumor suppressor roles in cancers. miR-92a and miR-17-3p are upregulated in tumor cells and associated with increased proliferation and tumorigenesis [ 19 , 20 ]. Among the best studied is miR-1246, which was first identified during sequencing of human stem cells in 2008 [ 21 ].…”

Section: Discussionmentioning

confidence: 99%

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF

2017

View full text Add to dashboard Cite

PurposeIntrinsic and acquired resistance limit the therapeutic benefits of inhibitors of oncogenic BRAF in melanoma. To identify microRNAs (miRNAs) associated with resistance to a BRAF inhibitor, we compared miRNA expression levels in three cell lines with different BRAF inhibitor sensitivity.Materials and MethodsmiRNA microarray analysis was conducted to compare miRNA expression levels. Real-time quantitative reverse-transcription polymerase chain reaction (qRT-PCR) was performed to confirm the expression of differentially expressed miRNAs. The cellular effects of miR-1246 were further examined by MTT assay, immunoblotting analysis, cell cycle analysis, flow cytometric assay of apoptosis, and autophagy assay.ResultsThe miRNA microarray analysis and qRT-PCR identified five miRNAs (miR-3617, miR-92a-1, miR-1246, miR-193b-3p, and miR-17-3p) with expression that was consistently altered in two BRAF inhibitor-resistant cell lines. Among the five miRNAs, a miR-1246 mimic significantly reduced the antiproliferative effects of the BRAF inhibitor PLX4720 in BRAF inhibitor–resistant A375P (A375P/Mdr) cells, suggesting that miR-1246 upregulation confers acquired resistance to BRAF inhibition. In particular, apoptosis was identified as a major type of cell death in miR-1246–transfected cells; however, necrosis predominated in mimic-control-transfected cells, indicating that the resistance to PLX4720 in miR-1246 mimic-transfected cells is predominantly due to a reduction in necrosis. Furthermore, we found that miR-1246 promoted G2/M arrest through autophagy as a way to escape cell death by necrosis and apoptosis in response to PLX4720. The promotion of BRAF inhibitor resistance by miR-1246 was associated with lowered levels of p-ERK.ConclusionThese results suggest that miR-1246 may be a potential therapeutic target in melanoma with acquired resistance to BRAF inhibitors.

show abstract

“…As an important fragment with biological functions, mature microRNA-126 (miRNA/miR-126) is associated with the angiogenesis, proliferation and differentiation of stem cells, as well as the development of various tumors (1)(2)(3)(4). Osteosarcoma, the most common primary malignant tumor, has exhibited a high prevalence in the past 20 years, therefore, the establishment of novel chemotherapy drugs for osteosarcoma is urgently required (5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate

Jiang

Cheng

2015

Oncology Letters

View full text Add to dashboard Cite

Abstract. The establishment of novel chemotherapy drugs for osteosarcoma is urgently required, and the mechanisms and effects of cisplatin (DDP) and methotrexate (MTX) in the current treatment of osteosarcoma have not been fully elucidated. The present study aimed to observe the effect of DDP, MTX and rapamycin on osteosarcoma cell proliferation and apoptosis, and to investigate the association between miR-126 and the effects of DDP and MTX in osteosarcoma cells. miR-126-overexpressing and -silencing lentiviral vectors were constructed, and MG63 and U-2 OS osteosarcoma cells were infected. An MTT assay was conducted to detect transfected cell proliferation, and the effects of the chemotherapy drugs on transfected cell apoptosis were detected by flow cytometry. The cell cycle of the transfected cells was analyzed via flow cytometry. As the miR-126-overexpressing and -silencing osteosarcoma cell lines were successfully constructed, it was observed that DDP and MTX inhibited osteosarcoma cell proliferation. With the decreased expression of miR-126, the sensitivity of osteosarcoma cells to DDP and MTX was reduced at the same concentration. The flow cytometry suggested that DDP and MTX could promote the apoptosis of osteosarcoma cells with overexpressed miR-126, whereas they could not significantly impact the apoptosis of the miR-126-silenced osteosarcoma cells. Meanwhile, DDP inhibited the cell cycle of the miR-126-overexpressing osteosarcoma cells. In conclusion, DDP and MTX inhibited the proliferation and promoted the apoptosis of the osteosarcoma cells, and these processes were dependent upon the expression of miR-126.

show abstract

Comparative analysis of melanoma deregulated miRNAs in the medaka and Xiphophorus pigment cell cancer models

Cited by 23 publications

References 43 publications

MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5

MiR-18a increased the permeability of BTB via RUNX1 mediated down-regulation of ZO-1, occludin and claudin-5

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF

MicroRNA-126 enhances the sensitivity of osteosarcoma cells to cisplatin and methotrexate

Contact Info

Product

Resources

About